Core Insights - Shineco Inc. announced two significant strategic advancements, including a technology services contract worth US$8.7 million with Xinke Future Biotechnology for microalgae-derived extracellular vesicles technology and a collaboration with Singapore's BICC for establishing a joint laboratory and technology exchange [1][4]. Group 1: Contract Details - The contract with Xinke Future Biotechnology focuses on developing a comprehensive R&D system for microalgae-derived extracellular vesicles technology, with a service period from August 25, 2025, to December 31, 2026 [2]. - Specific tasks under the contract include functional validation, overcoming large-scale separation and extraction bottlenecks, and developing at least two therapeutic products with regulatory support [2]. Group 2: Financial Implications - The contract provides immediate financial momentum, with a total value of US$8.7 million to be paid in phases, including an initial payment of US$560,000 already received [3]. - Subsequent payments are linked to R&D milestones, ensuring stable revenue recognition and long-term profit growth through the technology's scalable nature [3]. Group 3: Strategic Alliances - The collaboration with BICC aims to integrate their extensive network of over 3,000 agents in Southeast Asia with Shineco's domestic wellness channels, enhancing market reach [5][6]. - The partnership is expected to create synergies in R&D capabilities and application scenarios, supporting Shineco's strategy of combining domestic strength with international expansion [6]. Group 4: Leadership Statements - Shineco's CEO emphasized that the contract validates the company's strategy to monetize research and create near-term revenue, while the alliance with BICC strengthens both domestic and international growth engines [4][7]. - The company remains committed to advancing technology industrialization and international partnerships to deliver sustainable returns for shareholders [7].

Core Viewpoint - Shineco Inc. has entered a strategic cooperation agreement with BICC Pte Ltd to promote the implementation and redemption of "on-chain cell assets," marking a significant advancement in the RWA ecosystem from technical integration to real-world application [1][2]. Group 1: Strategic Collaboration - The partnership aims to establish a framework for standard-setting, compliance coordination, and scenario exploration to transition from technical feasibility to verifiable applicability [2][3]. - Plus Me Limited will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating digital identities and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers" [2][3]. - BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system, allowing users to redeem vouchers in designated BICC scenarios [2][3]. Group 2: Operational Framework - Shineco will focus on cell quality and offline network standardization, while BICC will emphasize user services and scenario integration [3]. - The collaboration will ensure end-to-end compliance for on-chain cell assets, covering storage, circulation, and application [3]. - The partnership aims to build a decentralized biological cell marketing ecosystem, with a vision to integrate standards and scenarios within a compliance framework [3]. Group 3: Company Background - Shineco, Inc. specializes in induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products, aiming to improve the quality of life through safe and efficient health products [5]. - BICC Pte Ltd, founded in 2024, focuses on stem cell treatments and artificial intelligence, leveraging proprietary technologies and a strategic presence across Asia [4].

Core Viewpoint - Shineco Inc. has entered into a partnership with Plus Me Limited to create a blockchain-based tokenization system for biological cellular assets, aiming to transform the global biological cell industry and enhance the commercial architecture of cell therapy [1][5][6] Group 1: Partnership and Agreement - The partnership involves a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" that facilitates the tokenization of Shineco's mesenchymal stem cells (MSCs) on the Ethereum blockchain [1][2] - Plus Me will provide full lifecycle digital custody of the MSCs, ensuring asset ownership rights through smart contracts and issuing unique non-fungible digital identifiers (NFDIs) for traceability [2][3] Group 2: Tokenization Framework - Plus Me will issue ERC-1400/ERC-20 compliant security tokens named "Cell Infusion Redemption Tokens," which can be redeemed at Shineco-affiliated Cell Therapy Centers [3] - The tokenization framework aims to address industry challenges such as high user costs and unverifiable product provenance, converting biological assets into tradable digital instruments [3] Group 3: Strategic Acquisitions - Shineco has acquired a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd., enhancing its off-chain infrastructure for token redemption [4] - This acquisition, along with the previously acquired Singapore firm Infiniclone, allows Shineco to establish a global storage and infusion network for on-chain and off-chain asset settlement [4] Group 4: Ecosystem Development - The collaboration will create an open-cell industry ecosystem where Plus Me provides tokenization SaaS to third parties, while Shineco offers its physical custody network [5] - Shineco's initiative positions the company as a global infrastructure provider for the cell economy, enabling rapid revenue scalability [5][6] Group 5: Industry Transformation - Shineco's asset tokenization protocol aligns with the industry's shift towards commercial scalability, marking the emergence of a decentralized biotech economy [6] - Token holders will gain governance rights, including future DAO voting, which will enhance the development of the global ecosystem in cell therapy [6]

Core Viewpoint - Shineco Inc. has established a Biological Cell Digital Business Division to integrate biological cell assets with blockchain technology, aiming to enhance the global distribution and sales of biological cell products [1][5]. Group 1: Division Objectives - The Division will utilize blockchain technology to create an efficient ecosystem for managing biological cell assets, focusing on standardized management, establishing an iPSC cell bank, and ensuring compliance for traceability [2]. - Key goals include developing blockchain tools for equity transfer to improve the efficiency of cell asset circulation [2]. Group 2: Benefits and Innovations - The Division is expected to allow medical and research institutions to allocate resources more flexibly and lower service access thresholds through flexible payment options [3]. - It aims to enhance collaboration across institutions, improve health data management, and introduce AI tools to optimize service experiences, making cell technology services more accessible globally [3]. Group 3: Leadership and Strategy - Mr. Lin Hongguang has been appointed as General Manager, bringing extensive experience in blockchain and digital assets, and will oversee strategic planning and operations of the Division [4]. - His responsibilities include developing standards for on-chain cell asset listings and expanding global collaborations to establish a distribution network for biological cell products [4]. Group 4: Industry Context - The bio-cell technology sector is identified as a key driver of the 'big health' industry, currently facing challenges such as low global circulation efficiency and high service thresholds [5]. - The establishment of the Biological Cell Digital Division is seen as a strategic investment to overcome these challenges and increase Shineco's market share in biological cell products [5].